Structural GenomiX has appointed Janice Culpepper as vice president of genomics and Doug Livingston as vice president of chemistry and new technology.
Culpepper’s most recent position was senior director of molecular technologies at Millennium Pharmaceuticals, where she directed high throughput DNA sequencing, cDNA library construction, genotyping, and protein production.
Livingston served as the director of chemistry at the Genomics Institute of the Novartis Research Foundation prior to joining Structural GenomiX.
DoubleTwist has made two promotions. Robert Williamson, formerly COO, is now president and COO, and Edward Kiruluta, formerly vice president of research and development, is now CTO.
Williamson will oversee all DoubleTwist internal operations, and will report to John Couch, chairman and CEO. Kiruluta will be responsible for setting the company’s technical strategy and overseeing company R&D.
Orchid Biosciences has hired Jack Ball, formerly president of Amersham Pharmacia Biotech North America, as senior vice president and general manager of its life sciences group. Ball will report directly to Dale Pfost, Orchid’s chairman and CEO.
Orchid announced a number of promotions in addition to Ball’s appointment, including Michael Boyce-Jacino, formerly vice president of R&D, who was promoted to CTO.